Compare ARDX & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARDX | OGN |
|---|---|---|
| Founded | 2007 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | 2014 | 2020 |
| Metric | ARDX | OGN |
|---|---|---|
| Price | $6.66 | $7.24 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 9 | 4 |
| Target Price | ★ $14.67 | $11.75 |
| AVG Volume (30 Days) | 3.8M | ★ 4.7M |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | ★ 1.06% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.72 |
| Revenue | $2,607,000.00 | ★ $6,216,000,000.00 |
| Revenue This Year | $35.64 | N/A |
| Revenue Next Year | $34.12 | $1.65 |
| P/E Ratio | ★ N/A | $10.49 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.50 | $6.18 |
| 52 Week High | $8.40 | $15.88 |
| Indicator | ARDX | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 46.75 | 40.57 |
| Support Level | $5.47 | $6.48 |
| Resistance Level | $6.69 | $7.74 |
| Average True Range (ATR) | 0.35 | 0.40 |
| MACD | -0.10 | -0.03 |
| Stochastic Oscillator | 58.24 | 40.10 |
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.